XML 85 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment and Geographic Information (Tables)
 6 Months Ended
Dec. 31, 2015
Segments and Geographic Information [Abstract]  
Schedule of Revenue by Geographic Location
We generated third-party net sales in the following geographic locations(1) during each of the periods presented below (in millions):
 
Six Months Ended
 
Fiscal Year Ended
 
December 31, 2015
 
June 27,
2015
 
June 28,
2014
 
June 29,
2013
Ireland
$
177.8

 
$
344.0

 
$
146.7

 
$
—

U.S.
1,695.1

 
3,303.6

 
3,291.6

 
2,978.1

Europe
720.1

 
613.6

 
217.2

 
164.0

All other countries(2)
176.5

 
342.7

 
405.3

 
397.7

 
$
2,769.5

 
$
4,603.9

 
$
4,060.8

 
$
3,539.8


(1)    We attribute net sales to countries based on sales location.
(2)    Includes sales generated primarily in Israel, Mexico, Australia, and Canada.
Schedule of Property and Equipment by Geographic Location
The net book value of property and equipment by location was as follows (in millions):
 
December 31,
2015
 
June 27,
2015
 
June 28,
2014
Ireland
$
1.3

 
$
1.4

 
$
2.0

U.S.
555.0

 
558.6

 
530.7

Europe
157.2

 
153.8

 
31.7

Israel
115.7

 
119.8

 
119.6

All other countries
57.0

 
98.8

 
95.9

 
$
886.2

 
$
932.4

 
$
779.9
Schedule of Segment Reporting Information, by Segment
Below is a summary of our results by reporting segment (in millions):
 
CHC
 
BCH (1)
 
Rx
 
Specialty Sciences (2)
 
Other
 
Unallocated
 
Total(3)
Six Months Ended December 31, 2015
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
1,384.7

 
$
627.9

 
$
543.4

 
$
168.4

 
$
45.1

 
$
—

 
$
2,769.5

Operating income (loss) (4)
$
209.2

 
$
(155.3
)
 
$
195.3

 
$
15.8

 
$
(19.5
)
 
$
(151.0
)
 
$
94.5

Operating income (loss) %
15.1
%
 
(24.7
)%
 
35.9
%
 
9.4
 %
 
(43.3
)%
 
—
%
 
3.4
%
Total assets
$
4,007.8

 
$
6,324.0

 
$
3,015.5

 
$
5,833.5

 
$
213.1

 
$
—

 
$
19,393.9

Capital expenditures
$
45.2

 
$
18.4

 
$
12.8

 
$
—

 
$
1.4

 
$
—

 
$
77.8

Property and equip, net
$
586.5

 
$
123.4

 
$
129.0

 
$
—

 
$
47.3

 
$
—

 
$
886.2

Depreciation/amortization
$
66.8

 
$
66.5

 
$
43.8

 
$
145.6

 
$
5.3

 
$
—

 
$
328.0

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year Ended June 27, 2015
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
2,750.0

 
$
401.1

 
$
1,001.1

 
$
344.0

 
$
107.7

 
$
—

 
$
4,603.9

Operating income (loss)
$
405.6

 
$
26.6

 
$
373.9

 
$
36.3

 
$
26.8

 
$
(121.5
)
 
$
747.7

Operating income (loss) %
14.7
%
 
6.6
 %
 
37.3
%
 
10.6
 %
 
24.9
 %
 
—
%
 
16.2
%
Total assets
$
4,381.6

 
$
6,441.1

 
$
2,667.9

 
$
5,979.0

 
$
251.0

 
$
—

 
$
19,720.6

Capital expenditures
$
80.5

 
$
3.6

 
$
42.9

 
$
0.5

 
$
6.4

 
$
3.1

 
$
137.0

Property and equip, net
$
600.0

 
$
122.5

 
$
124.1

 
$
—

 
$
85.8

 
$
—

 
$
932.4

Depreciation/amortization
$
123.2

 
$
38.3

 
$
85.1

 
$
291.6

 
$
10.6

 
$
—

 
$
548.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year Ended June 28, 2014
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
2,849.4

 
$
—

 
$
927.1

 
$
146.7

 
$
137.6

 
$
—

 
$
4,060.8

Operating income (loss)
$
413.1

 
$
—

 
$
349.8

 
$
(68.6
)
 
$
46.1

 
$
(173.4
)
 
$
567.0

Operating income (loss) %
14.5
%
 
—
 %
 
37.7
%
 
(46.7
)%
 
33.5
 %
 
—
%
 
14.0
%
Total assets
$
4,931.0

 
$
—

 
$
2,537.2

 
$
6,096.6

 
$
288.0

 
$
—

 
$
13,852.8

Capital expenditures
$
128.3

 
$
—

 
$
32.9

 
$
—

 
$
10.4

 
$
—

 
$
171.6

Property and equip, net
$
577.3

 
$
—

 
$
104.8

 
$
2.1

 
$
95.7

 
$
—

 
$
779.9

Depreciation/amortization
$
106.6

 
$
—

 
$
86.5

 
$
154.4

 
$
11.4

 
$
—

 
$
358.9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year Ended June 29, 2013
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
$
2,671.0

 
$
—

 
$
709.5

 
$
—

 
$
159.3

 
$
—

 
$
3,539.8

Operating income (loss)
$
401.8

 
$
—

 
$
263.2

 
$
—

 
$
48.9

 
$
(34.7
)
 
$
679.1

Operating income (loss) %
15.0
%
 
—
 %
 
37.1
%
 
—
 %
 
30.7
 %
 
—
%
 
19.2
%
Total assets
$
3,447.5

 
$
—

 
$
1,604.9

 
$
—

 
$
284.5

 
$
—

 
$
5,336.9

Capital expenditures
$
97.1

 
$
—

 
$
17.7

 
$
—

 
$
17.3

 
$
—

 
$
132.2

Property and equip, net
$
508.0

 
$
—

 
$
80.8

 
$
—

 
$
92.7

 
$
—

 
$
681.4

Depreciation/amortization
$
96.1

 
$
—

 
$
54.9

 
$
—

 
$
9.1

 
$
—

 
$
160.2



(1)     BCH includes activity subsequent to March 30, 2015.
(2)    Specialty Sciences includes activity subsequent to December 18, 2013.
(3)     Amounts may not cross-foot due to rounding.    
(4) 
    The BCH segment operating loss included a $185.1 million impairment charge on indefinite-lived intangible assets purchased in conjunction with the Omega acquisition (See Note 3 for more information). The Other operating loss included a $29.0 million impairment charge related to our India API held for sale assets (See Note 9 for more information).
Schedule of Sales by Major Product Category
The following is a summary of our net sales by category (in millions):
 
Six Months Ended
 
Fiscal Year Ended

December 31, 2015
 
June 27,
2015
 
June 28, 2014
 
June 29,
2013
CHC
 
 

 

 

Cough/Cold/Allergy/Sinus(1)
$
259.2

 
$
486.2

 
$
510.1

 
$
500.6

Analgesics(1)
200.3

 
441.7

 
504.0

 
536.0

Gastrointestinal(1)
204.2

 
395.3

 
400.1

 
388.8

Infant nutritionals
200.2

 
383.9

 
374.8

 
350.1

Smoking cessation
159.7

 
299.4

 
236.8

 
193.2

Vitamins, minerals and dietary supplements(1)
110.6

 
185.6

 
176.9

 
158.3

Animal health
62.3

 
156.9

 
178.0

 
123.2

Other CHC(1),(2)
188.2

 
401.0

 
468.7

 
420.9

Total CHC
1,384.7

 
2,750.0

 
2,849.4

 
2,671.1

BCH branded OTC products
627.9

 
401.1

 
—

 
—

Generic prescription drugs
543.4

 
1,001.1

 
927.1

 
709.5

Tysabri® royalties
168.4

 
344.0

 
146.7

 
—

Active pharmaceutical ingredients
45.1

 
107.7

 
137.6

 
159.3

Total net sales
$
2,769.5

 
$
4,603.9

 
$
4,060.8

 
$
3,539.8


(1)    Includes sales from our OTC contract manufacturing business.
(2) 
Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHC segment.